BioSpace News Archive

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its FHD-286 program will be highlighted in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the participation of Prue Plummer PhD, PT, Professor in the Department of Physical Therapy in the School of Health and Rehabilitation Sciences at the MGH Institute of Health Professions to its Therapeutic Experience Program.

Keystone Bio, a clinical-stage biotechnology company working to stop inflammatory-based disease at its source, announced the appointment of Michael Rafii, M.D., Ph.D., as Senior Medical Advisor in Neurology.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced that its management will present at the following investor conferences.

The International Society for Autonomic Neuroscience (ISAN) has elected The Feinstein Institutes for Medical Research’s Valentin Pavlov, PhD, as president in recognition of his dedication and research of the brain and autonomic nervous system, particularly in the regulation of inflammation and metabolism.

Hoth Therapeutics, Inc. announced that it received written notice from the NASDAQ Stock Market LLC on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on the NASDAQ Capital Market.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting in Louisville, Kentucky on November 12, 2022.

Prometheus Biosciences, Inc. (Nasdaq: RXDX) today reported financial results for the quarter ended September 30, 2022 and highlighted recent corporate progress.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.